T1	Participants 252 284	ndividuals > or =60 years of age
T2	Participants 492 594	Subjects with a negative history for HZ were randomized 1:1 to receive one dose of either formulation.
T3	Participants 182 227	herpes zoster (HZ) and postherpetic neuralgia
T4	Participants 595 667	Enrollment was stratified 1:2 by age (50 to 59 years and > or =60 years)
